PPARA and breast carcinoma: Since the pioneering findings of Huggins and Hodges in breast cancer, nuclear receptor (NR) agonists or antagonists have attained widespread use for therapy of hormone-sensitive tumors and hematologic neoplasias, and diversified NR ligands are still studied for extending indications, such as peroxisome-proliferator receptor α and γ (PPAR α/γ) agonists (13–17).